Deficiency for MicroRNA-582 does not impact dilated cardiomyopathy or heart failure induced by pressure overload in vivo
MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression and have been extensively implicated in cardiovascular development, homeostasis, and disease. Among them, microRNA-582 (miR-582) has been associated with several non-cardiac pathologies, yet its role in the heart remains poorly characterized despite significant cardiac expression. In this study, we investigated the functional significance of miR-582 in cardiac pathophysiology through both gain- and loss-of-function approaches. We observed differential expression of miR-582 in murine models of cardiomyopathy, prompting further mechanistic evaluation. Thus, we generated transgenic mice with cardiac-specific overexpression of miR-582 (TG-582) as well as miR-582 knockout (582-KO) mice. Neither model exhibited an obvious cardiac phenotype under basal conditions. Following pressure overload via transverse aortic constriction (TAC), both TG-582 and 582-KO mice developed hypertrophy and functional adaptations comparable to wildtype controls. Additionally, crossbreeding these models with Calsarcin-1-knockout (CS1-KO) mice, a model of dilated cardiomyopathy, did not modify the pathological phenotype. These results indicate that miR-582 does not play a determinative role in pressure overload-induced cardiac hypertrophy or in the progression of dilated cardiomyopathy. Our findings highlight the importance of rigorously controlled <i>in vivo</i> studies to accurately define the cardiac miRNA landscape and to guide future therapeutic strategies.
Authors
- Norbert Frey (ORCID: https://orcid.org/0000-0001-7611-378X)
- Christian Kühn (ORCID: https://orcid.org/0000-0002-6056-7442)
- Stefano De Martini (ORCID: https://orcid.org/0000-0002-2519-9138)
- Derk Frank
- Lucia Sophie Kilian
- Ashraf Yusuf Rangrez (ORCID: https://orcid.org/0000-0003-2630-9754)
- Frauke Senger
- Jakob Christoph Voran
- Nesrin Schmiedel
- Inka Dobberstein
Institutions
- Heidelberg University (DE)
- Roche Pharma AG (Germany) (DE)
- Leibniz Institute of Environmental Medicine (DE)
- University Hospital Schleswig-Holstein (DE)
- St. Vincentius-Kliniken (DE)
- German Centre for Cardiovascular Research (DE)
- CS Diagnostics (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.3389/fcell.2025.1661965
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Christian-Albrechts-Universität zu Kiel